Clinical Trial Update: Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola vaccine candidate in children in Gabon has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• rVSVΔG-ZEBOV-GP

Snippet

Sponsor: Centre de Recherche Médicale de Lambaréné | Conditions: Ebola Virus Disease | Phase 1, Phase 2 | Status: COMPLETED